Novavax (NVAX) Return on Equity (2011 - 2026)

Novavax's Return on Equity history runs 16 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Equity rose 2.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (up 2.0% YoY), while the FY2025 annual figure was 0.01%, down 1.0% from the prior year.
• Return on Equity was 0.01% for Q1 2026 at Novavax, up from 0.03% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.09% in Q1 2022 to a low of 0.22% in Q2 2025.
• Historically, Return on Equity has averaged 0.0% across 5 years, with a median of 0.01% in 2026.
• The sharpest annual moves came in 2022 and 2025: Return on Equity jumped 33 bps in 2022, then retreated 23 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then slipped by 29 bps to 0.01% in 2023, then sank by 58 bps to 0.0% in 2024, then plunged by 1050 bps to 0.03% in 2025, then jumped by 121 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.03% (Q4 2025), and 0.06% (Q3 2025), per Business Quant data.